GlobalData: Thermo Fisher to be major player in COVID-19 diagnostic tests following acquisition of Qiagen

Thermo Fisher Scientific is expected to produce millions of coronavirus (COVID-19) diagnostic tests following the acquisition of Qiagen for an approximate transaction value of US$11.5bn per share, says GlobalData, a leading data and analytics company.

GlobalData: Thermo Fisher to be major player in COVID-19 diagnostic tests following acquisition of Qiagen

Qiagen, a provider of molecular diagnostics and sample preparation technologies, offers a long list of nucleic acid amplification tests (NAATs) for the diagnosis and monitoring of infectious and genetic diseases, including real-time reverse-transcription (RT-PCR), which is currently being used to diagnose COVID-19.

Dara Lo, Medical Devices Analyst at GlobalData comments:

NAATs are highly used for the screening, confirmation, and monitoring of many infectious and genetic diseases due to their high sensitivity and accuracy. This is reflected in the human papilloma virus (HPV) tests market where NAATs are expected to be worth over US$371m, globally, by 2028 with Qiagen holding a significant percentage of the market share.

With a multi-million-dollar market in HPV NAATs, which contributes to 4.7% of all cancers world-wide, GlobalData expects an even larger market share for COVID-19, which can have up to 70% prevalence globally.”

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thermo Fisher Scientific Inc.. (2020, March 20). GlobalData: Thermo Fisher to be major player in COVID-19 diagnostic tests following acquisition of Qiagen. News-Medical. Retrieved on August 03, 2020 from https://www.news-medical.net/news/20200320/GlobalData-Thermo-Fisher-to-be-major-player-in-COVID-19-diagnostic-tests-following-acquisition-of-Qiagen.aspx.

  • MLA

    Thermo Fisher Scientific Inc.. "GlobalData: Thermo Fisher to be major player in COVID-19 diagnostic tests following acquisition of Qiagen". News-Medical. 03 August 2020. <https://www.news-medical.net/news/20200320/GlobalData-Thermo-Fisher-to-be-major-player-in-COVID-19-diagnostic-tests-following-acquisition-of-Qiagen.aspx>.

  • Chicago

    Thermo Fisher Scientific Inc.. "GlobalData: Thermo Fisher to be major player in COVID-19 diagnostic tests following acquisition of Qiagen". News-Medical. https://www.news-medical.net/news/20200320/GlobalData-Thermo-Fisher-to-be-major-player-in-COVID-19-diagnostic-tests-following-acquisition-of-Qiagen.aspx. (accessed August 03, 2020).

  • Harvard

    Thermo Fisher Scientific Inc.. 2020. GlobalData: Thermo Fisher to be major player in COVID-19 diagnostic tests following acquisition of Qiagen. News-Medical, viewed 03 August 2020, https://www.news-medical.net/news/20200320/GlobalData-Thermo-Fisher-to-be-major-player-in-COVID-19-diagnostic-tests-following-acquisition-of-Qiagen.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New high-resolution mass spectrometer expands the proven Thermo Scientific Orbitrap platform